期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 59, 期 3, 页码 1750-1755出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.04435-14
关键词
-
资金
- Austrian Science Fund (FWF) [I 661] Funding Source: researchfish
Clinical breakpoints (CBPs) have not been established for the Mucorales and any antifungal agent. In lieu of CBPs, epidemiologic cutoff values (ECVs) are proposed for amphotericin B, posaconazole, and itraconazole and four Mucorales species. Wildtype (WT) MIC distributions (organisms in a species-drug combination with no detectable acquired resistance mechanisms) were defined with available pooled CLSI MICs from 14 laboratories (Argentina, Australia, Canada, Europe, India, Mexico, and the United States) as follows: 10 Apophysomyces variabilis, 32 Cunninghamella bertholletiae, 136 Lichtheimia corymbifera, 10 Mucor indicus, 123 M. circinelloides, 19 M. ramosissimus, 349 Rhizopus arrhizus, 146 R. microsporus, 33 Rhizomucor pusillus, and 36 Syncephalastrum racemosum isolates. CLSI broth microdilution MICs were aggregated for the analyses. ECVs comprising >= 95% and >= 97.5% of the modeled populations were as follows: amphotericin B ECVs for L. corymbifera were 1 and 2 mu g/ml, those for M. circinelloides were 1 and 2 mu g/ml, those for R. arrhizus were 2 and 4 mu g/ml, and those for R. microsporus were 2 and 2 mu g/ml, respectively; posaconazole ECVs for L. corymbifera were 1 and 2, those for M. circinelloides were 4 and 4, those for R. arrhizus were 1 and 2, and those for R. microsporus were 1 and 2, respectively; both itraconazole ECVs for R. arrhizus were 2 mu g/ml. ECVs may aid in detecting emerging resistance or isolates with reduced susceptibility (non-WT MICs) to the agents evaluated.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据